CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
FT596 +1 moredrug
Likely dose
Rituximab 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04555811
NCT04555811Phase 1Completed
CompareCT.gov

FATE FT596 With Rituximab as Relapse Prevention in High Risk Patients After Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Masonic Cancer Center, University of Minnesota·interventional·Posted Sep 21, 2020·Updated Jul 9, 2024

In Brief

A Phase 1 clinical trial evaluating FT596 and Rituximab for NHL and 3 related conditions. Completed, enrolled 7 participants across 2 sites.

Detailed Summary

This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedSep 21, 2020
Enrollment StartSep 22, 2020
Primary CompletionFeb 8, 2023
Study CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.8 years ago

Interventions

FT596drug

FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.

Rituximabdrug

Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion